DERMTECH INC (DMTK)

Company Profile

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in San Diego, California and currently employs 278 full-time employees. The company went IPO on 2017-06-20. The firm is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. Its technology enhances early melanoma detection by non-invasively detecting genomic markers associated with melanoma to identify higher risk lesions at their earliest stages to rule out melanoma. The company provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. Its DermTech Melanoma Test (the DMT) facilitates the clinical assessment of pigmented skin lesions that raise the concern for melanoma. Its commercial test addresses unmet needs in the diagnostic pathway of pigmented skin lesions, dark-colored patches of skin often referred to as moles. The company markets the DMT under the name Pigmented Lesion Assay (PLA). The company is also focuses on products to assess precancerous genomic changes associated with UV sun exposure.

Company Info

DERMTECH INC

12340 El Camino Real

San Diego CALIFORNIA 92037

P: 18584504222

CEO: John Dobak

Employees: 278

Website: https://dermtech.com/